X

Pharmaceutical APIs

Divi’s Laboratories Reports Steady Q3 FY26 Growth Amid Labour Code Impact

Divi's Laboratories Limited (NSE: DIVISLAB), a leading Indian API manufacturer, posted consolidated total income of INR 2,692 crores for Q3…

Aarti Pharmalabs Limited reports sequential margin recovery in Q3 FY26 as CDMO transit impact weighs on revenue

Aarti Pharmalabs Limited (NSE: AARTIPHARM, BSE: 543748) reported a sequential improvement in operating performance in the quarter ended Dec. 31,…